Abstract
Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Current Gene Therapy
Title:The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy
Volume: 15 Issue: 1
Author(s): X.G. Chen and W.T. Godbey
Affiliation:
Keywords: Alternative splicing, expression-targeting, gene delivery, SNP, SPP1.
Abstract: Regulatory elements of the osteopontin (opn) gene are attractive candidates for expressiontargeted gene therapy because numerous malignant cancers are marked by opn overexpression. The maximum opn promoter (Popn)-driven reporter intensity obtained for tested cancer cell lines was as strong (102.69%) as positive-control transfections. At the same time, Popn-driven reporter expression was reduced by ~90% in non-cancer cell lineages. Deletion analysis of the -922 bp region opn promoter did not confirm published reports of a repressor area within 922 bases upstream of the transcriptional start site. Further enhancements to targeting and expression were obtained through incorporation of single-nucleotide polymorphisms (SNPs) into the promoter sequence. It was found that the SNPs -443C, -155GG, -66T led to increased Popn-driven transfection in cancer cells (fold increase of 1.23 ~ 3.48), with a concomitant decrease in reporter expression in normal controls (fold change of 0.69). Further investigations to confirm a correlation between endogenous opn mRNA levels and Popn-driven reporter expression produced a surprising lack of correlation (R2=0.24). However, taking into account opn mRNA splicing variants showed a strong negative correlation between mRNA levels of the variant opn-a and P opn-driven transgene activity (R2=0.95). These data have implications on how future searches for expression-targeting promoters should be conducted.
Export Options
About this article
Cite this article as:
Chen X.G. and Godbey W.T., The Potential of the Human Osteopontin Promoter and Single-Nucleotide Polymorphisms for Targeted Cancer Gene Therapy, Current Gene Therapy 2015; 15 (1) . https://dx.doi.org/10.2174/1566523214666141127094033
DOI https://dx.doi.org/10.2174/1566523214666141127094033 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers.
Programmed cell death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review of the Current Role of Proton Therapy in Modern Oncology
Current Drug Therapy Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Identification of a Linear Epitope Recognized by a Monoclonal Antibody Directed to the Heterogeneous Nucleoriboprotein A2
Protein & Peptide Letters Anti-Proliferative Activity of Synthetic Ajoene Analogues on Cancer Cell-Lines
Anti-Cancer Agents in Medicinal Chemistry Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Oral Mucosal Immunization: Recent Advancement and Future Prospects
Current Immunology Reviews (Discontinued) Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Chemical Synthesis, Mechanism of Action and Anticancer Potential of Medicinally Important Thiazolidin-2,4-dione Derivatives: A Review
Mini-Reviews in Medicinal Chemistry Targeting Aurora Kinases in Cancer Treatment
Current Drug Targets ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Meet Our Editorial Board Member
Pharmaceutical Nanotechnology Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules
Current Drug Targets Vesicovaginal Fistula
Current Women`s Health Reviews Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology
Current Cancer Drug Targets Principles of Minimally Invasive Parathyroidectomy
Current Medical Imaging Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Towards the Molecular Imaging of Prostate Cancer Biomarkers Using Protein-based MRI Contrast Agents
Current Protein & Peptide Science Alpha1-Antitrypsin Deficiency: Transition of Care for the Child With AAT Deficiency into Adulthood
Current Pediatric Reviews Application of Machine Learning Approaches for Protein-protein Interactions Prediction
Medicinal Chemistry Multi-Target Mining of Alzheimer Disease Proteome with Hansch’s QSBR-Perturbation Theory and Experimental-Theoretic Study of New Thiophene Isosters of Rasagiline
Current Drug Targets